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Abstract. Pneumothorax in patients with progressive 
systemic sclerosis (PSS) often presents as a difficult‑to‑treat 
disease. Autologous blood-patch pleurodesis has previ-
ously been used for the treatment of pneumothorax. Blood 
outside its own environment is an irritant; therefore, chest 
physicians must watch closely for an allergic reaction. The 
injection is simple, painless, causes no side effects, is an 
inexpensive treatment for pneumothorax and is available not 
only in patients with persistent air leak but also in those with 
residual air space. A case is reported here of blood-patch 
pleurodesis for pneumothorax in lung fibrosis due to PSS. 
As an alternative therapy for difficult‑to‑treat pneumothorax 
in patients with PSS with persistent air leak and residual air 
space, autologous blood-patch pleurodesis would be one of 
the treatment options.
Introduction
Pneumothorax is not a rare complication of lung fibrosis due 
to progressive systemic sclerosis (PSS); however, a number of 
patients with PSS who have extensive pulmonary fibrosis with 
enlarged sub-pleural blebs and honeycomb lungs have been 
shown to develop pneumothorax. Various treatment options 
have been described (1). Surgery is a treatment option for 
recurrent and refractory pneumothorax. Chemical pleurodesis 
with talc or minocycline is also another treatment option, 
but there were complication with deterioration of pulmo-
nary fibrosis especially in patients with pulmonary fibrosis. 
However, the success rate of the of PSS patients with pneumo-
thorax appeared to be unsatisfactory. A case is reported here 
following successful treatment with a blood patch introduced 
into the chest via an intercostal chest drain. The purpose of 
this case report is to report the usefulness of this successful 
treatment.
Case report
A 69-year-old female was admitted to the Mito Medical 
Center (Mito, Japan) due to dyspnea on exertion and right 
chest pain lasting all day. Three years previously she was 
diagnosed as having PSS with lung fibrosis (Fig. 1). Since 
then, the patient had experienced a pneumothorax on the 
right side several times and had subsequently received a 
video-assisted thoracoscopic surgery for persistent pneumo-
thorax.
Physical examination on admission revealed decreased 
respiratory sound in the right lung and diffuse fine crackles 
in both lungs. Skin thickening and tightness were observed 
on the fingers of both hands. Laboratory data on admis-
sion were as follows: White blood cell, 4,900/µl; C-reactive 
protein, 3.77 mg/dl; anti-nuclear antibody, 1:640; anti-centro-
mere antibody, 1:640; rheumatoid factor, 4 U/ml. Tests for 
anti-neutrophil cytoplasmic antibodies to proteinase 3 and 
myeloperoxidase and anti-ribonucleoprotein and -topoisom-
erase 1 antibodies were negative. A chest radiograph revealed 
pneumothorax in the right lung, and reticulonodular opacities 
predominant in the bilateral lower lungs (Fig. 2). A 20 French 
intercostal chest tube (Argyle thoracic catheter, Covidien, 
Tokyo, Japan) was inserted into the pleural cavity, but the 
air leak continued and no improvement of the pneumothorax 
was obtained. The patient declined surgery; therefore, 
considering the deterioration of her respiratory condition 
following pleurodesis by other chemical agents, pleurodesis 
through the instillation of an autologous blood-patch was 
selected. A total of 50 ml autologous blood was injected via 
the chest tube. The tube was clamped for 3 h and connected 
to suction. The procedure was repeated twice over the next 
two days. Discontinuation of the air leak was achieved in 
three days and the chest tube was removed. Eight months 
later the patient was still well and attending the outpatient 
clinic without any recurrent pneumothorax (Fig. 3). This 
therapy was approved by the National Health Insurance of 
Japan as a postoperative persistent air leak therapy and by 
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the Ethics Committee of the Mito Medical Center, University 
of Tsukuba-Mito Kyodo General Hospital (Mito, Japan). 
Informed consent was obtained from the patient. 
Discussion
PSS is a systemic disease that sometimes affects the lungs, 
resulting in lung fibrosis (1). Diffuse interstitial fibrosis is the 
most common pulmonary manifestation and pneumothorax 
is usually associated with the pulmonary complication of 
interstitial fibrosis (1). The underlying mechanism of pneu-
mothorax is believed to result from the rupture of acquired 
subpleural cystic spaces associated with the diffuse inter-
stitial fibrosis (2). In patients with PSS with interstitial 
fibrosis, the distinctive rigidity of lung parenchyma may 
prevent pre-expansion of the ruptured lung. Additionally, 
immunosuppressants including corticosteroids, which are 
frequently used for PSS, may aggravate persistent air leak; 
therefore, pneumothorax in patients with PSS often presents 
as a difficult‑to‑treat disease and prognosis is predicted to 
be poor. Chemical pleurodesis with tetracycline or talc 
has been successfully used (3-5), but pleurodesis is more 
usually performed once the air leak has resolved. Chemical 
pleurodesis using such agents can contribute to the onset of 
acute exacerbation of the interstitial fibrosis (4). Furthermore, 
if pleurodesis can be successfully achieved, the development 
of constrictive respiratory impairment may occur due to 
pleural thickening as a result of the chemical pleurodesis. 
If there is no improvement despite conservative treatment, 
a more invasive approach may be necessary. Video-assisted 
thoracic surgery is the next option for patients with recurrent 
pneumothorax and those for whom conservative treatment 
was not successful (5,6). Due to the severity of their underlying 
disease itself and their respiratory condition, these patients 
are often not suitable candidates for surgical treatment. As a 
consequence, their optimal management may be eventful. As 
an alternative therapy, autologous blood-patch pleurodesis 
has been used for the treatment of pneumothorax (7-9). 
Blood outside its own environment is an irritant; therefore, 
chest physicians must watch closely for an allergic reaction. 
The injection is simple, painless, causes no side effects and 
is an inexpensive treatment for pneumothorax available not 
only for patients with persistent air leak but also those with 
residual air space (10). In the case reported here, recurrent 
pneumothorax developed shortly after surgical therapy 
for the disease and there was persistent air leak as well as 
residual air space. Due to the high risk of deterioration of 
the respiratory condition of the patient by tight chemical 
pleurodesis, we selected to seal the pleural space with the 
injection of autologous blood as a successful pleurodesis 
agent in the treatment of recurrent pneumothorax. 
In conclusion, as an alternative therapy for difficult‑to‑treat 
pneumothorax in patients with PSS with persistent air leak and 
residual air space, autologous blood-patch pleurodesis would 
be one of the treatment options.
Figure 1. Chest computed tomography scan showing lung fibrosis at the time 
of diagnosis of progressive systemic sclerosis.
Figure 2. Chest radiograph reveals right lung pneumothorax, and reticulo-
nodular opacities predominant in the bilateral lower lungs.
Figure 3. Chest radiograph 8 months after the autologous blood‑patch 
pleurodesis shows no recurrence of pneumothorax.
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